OMEGA-3 POLYUNSATURATED FATTY ACIDS FROM ALGAE

最近的流行病学和临床调查表明 膳食补充剂之间的显著相关性 多不饱和脂肪酸，特别是omega-3多不饱和脂肪酸， 并降低冠心病的发病率。临床 人们的兴趣主要集中在omega-3多不饱和脂肪酸在 治疗高胆固醇血症和高甘油三酯血症。 目前，omega-3多不饱和脂肪酸的唯一来源是石油 从某些海鱼身上。然而，许多种类的藻类也 生产大量的omega-3多不饱和脂肪酸，我们相信 这组生物体可以提供无价的供应来源 用于临床试验和/或食品添加剂测试的omega-3多不饱和脂肪酸 使用藻类单一养殖。技术含量的确定 这一战略的可行性(第一阶段)将涉及以下近 任期目标： -在几个产生omega-3多不饱和脂肪酸的藻类中建立 文化。 --优化生长条件，确定最大 Omega-3多不饱和脂肪酸生产力。 -提取和纯化制备中的omega-3多不饱和脂肪酸 数量。 如果确定了相对于鱼油来源的显著优势， 第二阶段的工作将包括扩大生产和努力 目标是增加我们的欧米茄-3多不饱和脂肪酸的具体产量 通过菌种改良和基因改造获得藻类来源。

Recent epidemiological and clinical investigations have indicated a significant correlation between dietary supplements of polyunsaturated fatty acids (PUFA), especially omega-3 PUFA's, and reduced incidence of coronary heart disease. Clinical interests have focused on potential usage of omega-3 PUFA's in the treatment of hypercholesteremia and hypertriglyceridemia. At present the only source of omega-3 PUFA's is oil expressed from certain marine fishes. However, many species of algae also produce large amounts of omega-3 PUFA's and we believe that this group of organisms could provide an invaluable supply source of omega-3 PUFA's for clinical trials and/or food additive testing using algal monoculture. Determination of the technological feasibility (Phase I) of this strategy will involve the following near term objectives: - Establish in several omega-3 PUFA producing algal species in culture. - Optimize the growth conditions and determine the maximum omega-3 PUFA productivities. - Extract and purify the omega-3 PUFA's in preparative quantities. If significant advantages over the fish oil source are identified, the Phase II effort will involve scale-up production and an effort targeted to increase the specific omega-3 PUFA outputs from our algal sources by strain improvement and genetic modification.